Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,704.61% | 57.75% | 116.69% | 14.00% | 16.61% |
| Total Depreciation and Amortization | -63.64% | 460.40% | 56.02% | 0.99% | -93.86% |
| Total Amortization of Deferred Charges | -- | -- | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 5,288.91% | -81.36% | -102.89% | -9.93% | 92.00% |
| Change in Net Operating Assets | 460.55% | -469.02% | -395.89% | -184.36% | 219.69% |
| Cash from Operations | -749.31% | -33.90% | 88.08% | -19.89% | 65.82% |
| Capital Expenditure | 100.00% | 19.33% | 100.00% | -100.00% | -170.00% |
| Sale of Property, Plant, and Equipment | -- | -- | 1,900.00% | -79.38% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 19.33% | 702,100.00% | -7,006.12% | -170.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -50.15% | 0.00% | 0.00% |
| Issuance of Common Stock | 228.32% | -- | 16,305.97% | -90.75% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 52.65% | -- | -- | -- | -- |
| Cash from Financing | 68.65% | 130.60% | 1,118.45% | -99.99% | 1,879.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -92.94% | -15.39% | 254.96% | -760.16% | 230.51% |